Stockreport

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

BridgeBio Oncology Therapeutics, Inc.  (BBOT) 
PDF BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Ka and a synergistic portfolio that is desig [Read more]